IL1B and atherosclerosis: Everett et al. reported a gratifying result by using IL1B inhibitor canakinumab to effectively inhibit inflammation and improve cardiovascular disease outcomes, suggesting that inflammation is a key factor driving atherosclerosis and targeting immune inflammation.